ArticleMolecules (Basel, Switzerland)2025
Chemical Characterization and Bioactivities of Sericin Extracted from Silkworm Cocoons from Two Regions of Portugal.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular and Pharmacokinetic Rationale for the Use ofMolecules (Basel, Switzerland) · 2026Article
- Antioxidant and immunomodulatory activities of sericin and its applications in tumor prevention and treatment.American journal of translational research · 2026Review
- Analysis of the Phenolic Profile ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sericin has been characterized as demonstrating a variety of bioactivities, establishing it as a valuable resource for biomedical and pharmaceutical applications. The diverse biological activities of sericin are likely linked to its unique biochemical composition and properties. This study aimed to assess the effect of origin, seasonality, and amino acid composition on the bioactivity of sericin samples from two Portuguese regions compared to commercial sericin. The amino acid profile was analyzed using HPLC-FLD. Moreover, several bioactivities were assessed through in vitro assays, including antiproliferative effects, cell migration, antimicrobial activity, anticoagulant properties, antioxidant capacity, and anti-inflammatory effects. The results obtained in this work revealed that the origin and season affect the sericin amino acid profile. In its pure state, sericin exhibited a low content of free amino acids, with tyrosine being the most abundant (53.42-84.99%). In contrast, hydrolyzed sericin displayed a higher amino acid content dominated by serine (54.05-59.48%). Regarding bioactivities, the sericin tested did not demonstrate antioxidant or anti-inflammatory potential in the conducted tests. Notwithstanding, it showed antiproliferative activity in contact with human tumor cell lines at a minimum concentration of 0.52 mg/mL. Regarding antimicrobial activity, sericin had the capacity to inhibit the growth of the bacteria and fungi tested at concentrations between 5 and 10 mg/mL. Additionally, sericin demonstrated its capacity to prolong the coagulation time in pooled human plasma, indicating a potential anticoagulant activity. In addition, the origin and season also revealed their impact on biological activities, and sericin collected in Bragança in 2021 (S3) and 2022 (S4) demonstrated higher antiproliferative, antibacterial, and anticoagulant potentials. Future studies should focus on optimizing sericin's bioactivities and elucidating its molecular mechanisms for clinical and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.